**4.1 Recombinant human BMP products**

BMP-2, 4, and 7 are strong accelerating factors of bone induction. Currently, BMP-2 and BMP-7 have been shown in clinical studies to be beneficial in the therapy of a variety of bone-related conditions including delayed union and non-union. BMP-2 (Medtronic Co.Ltd.) and BMP-7 (Stryker Biotech Co.Ltd.) have received Food and Drug Administration (FDA) approval for human clinical uses (fractures of long bones, inter-vertebral disk regeneration), by delivery in purified collagen matrix or ceramics. Moreover, the BMP-2 product has been approved for certain dental applications. BMP-7 has also found use in the treatment of chronic kidney disease. In 2002, Curis licensed BMP-7 to Ortho Biotech Products, a subsidiary of Johnson & Johnson.
